Dr Vulfovich speaks with ecancertv at the Best of ASCO 2016 about novel treatments for ovarian cancer.

Using BRCA mutations as a marker, he describes the significance of PARP inhibitor treatment on survival.

For the initial announcement of results from olaparib in ovarian cancer, you can watch an interview with Dr Jonathan Ledermann here.